- Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
- Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come